Details of Disease

General Information of Disease (ID: DISXVPHM)

• Disease Name: Diabetic foot ulcer
• Disease Class: BD54: Diabetic foot ulcer
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISXVPHM: Diabetic foot ulcer
• ICD Code:
  ICD-11: ICD-11: BD54
  ICD-9: ICD-9: 707
  Expand ICD-11: 'BD54
  Expand ICD-9: 707
• Disease Identifiers:
  MedGen ID: 264162
  SNOMED CT ID: 371087003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alprostadil	DMWH7NQ	Approved	Small molecular drug	[1]
Apligraf	DMAO2GX	Approved	NA	[2]
CT-102	DMB8PF3	Approved	NA	[1]
Daprodustat	DMRNGD2	Approved	Small molecular drug	[3]
Doxycycline	DM7ICNU	Approved	Small molecular drug	[4]
HEGF	DMN0S1G	Approved	NA	[1]
Nitroglycerin	DMQ2491	Approved	Small molecular drug	[1]
Pexiganan	DMZBXSO	Approved	Small molecular drug	[2]
Prezatide copper acetate	DMAFJ3V	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 32 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALLO-ASC-DFU	DMYZTZV	Phase 3	Cell therapy	[5]
Ch14.18 mab	DMMDBF5	Phase 3	Monoclonal antibody	[6]
CureXcell	DMFJMPT	Phase 3	NA	[7]
Donaperminogene seltoplasmid	DMH8IT5	Phase 3	Gene therapy	[8]
DSC-127	DMM0HAE	Phase 3	Small molecular drug	[9]
Granexin	DMJICVP	Phase 3	NA	[10]
Granexin gel	DMZS2R7	Phase 3	NA	[11]
ICX-PRO	DM88BYM	Phase 3	NA	[12]
INL-002	DMZV8OU	Phase 3	NA	[3]
PDGF-BB	DMMBC5W	Phase 3	NA	[13]
Talactoferrin	DMV7T64	Phase 3	NA	[14]
VM-202	DMSW80U	Phase 3	NA	[11]
White blood cell therapy	DMMA6Z3	Phase 3	NA	[15]
ACT-1	DMAKM5I	Phase 2	NA	[16]
CVBT-141B	DM51X8Q	Phase 2	NA	[3]
CVBT-141B topical	DMFM2NM	Phase 2	NA	[11]
DCB-WH1	DMKL2XT	Phase 2	NA	[17]
Dermacyn	DMEYNJN	Phase 2	NA	[18]
GAM-501	DMAEWS1	Phase 2	NA	[19]
HO/03/03	DMA6HQJ	Phase 2	NA	[20]
IL22-Fc	DMXT203	Phase 2	NA	[11]
MBN-101	DMLYUEO	Phase 2	NA	[21]
MRE-0094	DMQR23W	Phase 2	Small molecular drug	[1]
Nexagon	DMNVCY2	Phase 2	NA	[22]
PDA-002	DMX60IL	Phase 2	NA	[3]
RG7880	DM452RF	Phase 2	NA	[23]
ATG002	DMB5X7Z	Phase 1/2	NA	[24]
Galnobax	DMQU4EI	Phase 1/2	NA	[3]
Nu-3	DM1KUOR	Phase 1/2	NA	[11]
BRX-005	DMTDWIE	Phase 1	Small molecular drug	[25]
ExpressGraft	DMUTHWF	Phase 1	NA	[26]
WPP-201	DM1VY1G	Phase 1	NA	[27]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rusalatide acetate	DMCI6NK	Discontinued in Phase 2	Small molecular drug	[28]
Telbermin	DMIDGZU	Discontinued in Phase 2	NA	[1]
PLR-15	DMLY964	Terminated	NA	[29]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PDGF gene therapy	DMSO3HM	Investigative	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT00764361) Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04569409) Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.. U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of United Therapeutics.
• [7] ClinicalTrials.gov (NCT02130310) Evaluation of CureXcell in Treating Chronic Venous Leg Ulcers. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT02563522) Safety and Efficacy Study of VM202 in the Treatment of Chronic Non-Healing Foot Ulcers. U.S. National Institutes of Health.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8300).
• [10] ClinicalTrials.gov (NCT02667327) A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] ClinicalTrials.gov (NCT00232973) Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers. U.S. National Institutes of Health.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5039).
• [14] ClinicalTrials.gov (NCT00706862) Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of Macrocure.
• [16] Clinical pipeline report, company report or official report of FirstString Research.
• [17] ClinicalTrials.gov (NCT00709514) Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT00516958) Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn Wound Care to Treat Mild Diabetic Foot Infections. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT00493051) Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT00926068) Safety and Efficacy of HO/03/03 10 in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT02436876) Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites. U.S. National Institutes of Health.
• [22] Clinical pipeline report, company report or official report of CoDa Therapeutics.
• [23] Clinical pipeline report, company report or official report of Roche.
• [24] ClinicalTrials.gov (NCT00316537) Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers. U.S. National Institutes of Health.
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013054)
• [26] ClinicalTrials.gov (NCT04134143) An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers. U.S.National Institutes of Health.
• [27] ClinicalTrials.gov (NCT00663091) A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers. U.S. National Institutes of Health.
• [28] Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia. Wound Repair Regen. 2000 Nov-Dec;8(6):517-29.
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022815)